Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) shares gapped down prior to trading on Tuesday. The stock had previously closed at $3.82, but opened at $3.58. Anbio Biotechnology shares last traded at $3.7760, with a volume of 391 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has an average rating of “Sell”.
Read Our Latest Stock Analysis on NNNN
Anbio Biotechnology Stock Performance
The business’s 50-day moving average price is $4.70 and its two-hundred day moving average price is $15.98.
Hedge Funds Weigh In On Anbio Biotechnology
A hedge fund recently bought a new position in Anbio Biotechnology stock. State Street Corp acquired a new stake in shares of Anbio Biotechnology (NASDAQ:NNNN – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,608 shares of the company’s stock, valued at approximately $161,000.
Anbio Biotechnology Company Profile
Anbio Biotechnology is a medical technology company focused on in vitro diagnostic products used to detect and monitor health conditions. Its offerings include diagnostic testing systems and related products designed for clinical and point-of-care settings. The company’s product portfolio includes testing equipment and diagnostic reagents, supporting the analysis of patient samples. These tools are intended to help healthcare providers obtain test results outside or alongside conventional laboratory workflows.
Further Reading
- Five stocks we like better than Anbio Biotechnology
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
